Scinai Immunotherapeutics
Tamar Ben-Yedidia is currently the Chief Scientific Officer at BiondVax Pharmaceuticals Ltd. They have extensive experience in managing preclinical and clinical studies, including Phase I/II and Phase II trials. Prior to their current role, they worked as a Professor Assistant at Weizmann Institute of Science and as an R&D Lab Manager at Biotechnology general. Tamar holds a Ph.D. in Immunology from Weizmann Institute of Science and an MSc in Immunology from Tel Aviv University.
This person is not in any offices
Scinai Immunotherapeutics
1 followers
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs. Company website: www.scinai.com